Articles tagged "Heart transplant patients"

2022 American Transplant Congress
Heart-Kidney Transplantation Appears to Be Acceptable for Patients Greater Than 65 Years of Age
T. Singer-Englar, M. Kittleson, J. Patel, N. Patel, S. Kim, D. Chang, E. Kransdorf, L. Czer, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Heart-kidney transplantation (HKTx) has been found to improve survival in patients with advanced kidney disease who undergo heart transplantation. It is not known whether…
2022 American Transplant Congress
Use of Pronase to Identify HLA Crossmatch Antibody Interference
N. Hendren¹, C. Lacelle¹, S. Carter¹, J. L. Grodin¹, E. Hardin², M. Farr³, S. Garg¹
¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
*Purpose: Solid organ transplant centers should maintain vigilance that antibody therapies can impact HLA crossmatch results.*Methods: N/A*Results: A 46-year-old man with Mayo stage IV cardiac…
2022 American Transplant Congress
Phenytoin To Expedite Sirolimus & Tacrolimus Elimination: A Case Report
A. Lemke, B. A. Boilson, R. Razonable, S. A. Bernard
Mayo Clinic, Rochester, MN
*Purpose: Sirolimus (SIR), a mammalian target of rapamycin inhibitor (mTORi), may be used with or without a calcineurin inhibitor after heart transplant (HT). The anti-proliferative…
2022 American Transplant Congress
The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection
P. Shah¹, R. Cheng², H. Eisen³, B. D. Lowes⁴, L. Lourenco Jenkins⁵, Y. Fu⁵, K. Qu⁵, J. Teuteberg⁶, E. DePasquale⁷
¹Inova Heart and Vascular Institute, Falls Church, VA, ²University of Washington Heart Institute, Seattle, WA, ³Pennsylvania State University, Hershey, PA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵CareDx, Brisbane, CA, ⁶Stanford University, Stanford, CA, ⁷University of Southern California, Los Angeles, CA
*Purpose: Changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the dd-cfDNA…
2022 American Transplant Congress
Impact of Cytomegalovirus Infection on mRNA Expression Utilizing the Molecular Microscope in Heart Transplant Recipients
S. S. Patlolla, J. Van Zyl, K. Castro, S. Mckean, R. Patel, S. Carey, A. Alam, S. Hall
Cardiology, Baylor University Medical Center, Dallas, TX
*Purpose: Little is known about the effect of CMV infection on transplant messenger RNA expression utilizing the molecular microscope (MMDx) in the absence of acute…
2022 American Transplant Congress
Impact of Donor and Recipient Characteristics on Early Post-Transplant Donor-Derived Cell-Free DNA (dd-cfDNA) Scores
A. Alam¹, J. Zeng², J. Teuteberg³, S. Hall¹
¹Baylor University Medical Center, Dallas, TX, ²CareDx, Brisbane, CA, ³Stanford University, Stanford, CA
*Purpose: Dd-cfDNA (AlloSure, CareDx; Brisbane, CA) has been demonstrated to detect allograft injury after heart transplantation in a large and diverse patient cohort in the…
2022 American Transplant Congress
Transition Program for Young Adults with Solid Organ Transplant a Single Center Protocol
H. Y. Lee
Program for Pediatric Cardiomyopathy, Heart Failure, and Cardiac Transplantation, Columbia University Irving Medical Center, New York, NY
*Purpose: The transition process for young adult solid organ transplant patient is an important clinical milestone in a transplant patient's life. Evidenced based research demonstrates…
2022 American Transplant Congress
Fontan versus Non-Fontan Combined Heart-Liver Transplantation: Proceed but Cautiously
I. A. Ziogas, W. K. Wu, M. Izzy, A. Shingina, C. Benson, K. L. Mishra, A. S. Shah, N. L. Do, W. G. McMaster, J. N. Menachem, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Combined heart-liver transplantation (CHLT) is increasing, corresponding with a growing prevalence of Fontan-associated end-organ damage. We aimed to describe our contemporary institutional experience with…
2022 American Transplant Congress
A Sign of Things to Come? Clinical Markers After Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients
D. T. Kim¹, E. J. Henricksen², B. M. Zhang³, J. J. Teuteberg¹, Y. Moayedi⁴, H. I. Luikart¹, J. Han⁵, B. Wayda¹, K. Khush¹
¹Cardiology, Stanford University, Stanford, CA, ²Transplant, Stanford Health Care, Stanford, CA, ³Pathology, Stanford University, Stanford, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Cardiology, University of Chicago, Chicago, IL
*Purpose: Endomyocardial biopsy (EMBx) has historically been the standard of care for surveillance post heart transplant (HTx), but is limited by sample area and interpretation.…
2022 American Transplant Congress
The Post-operative Clinical Outcomes Of 59 Tanrp Cases In An International Cohort
J. Louca¹, N. Patel¹, S. Messer², J. Chindu², S. Large²
¹Cambridge University, Cambridge, United Kingdom, ²Royal Papworth Hospital, Cambridge, United Kingdom
*Purpose: Heart transplantation is an immensely effective service and is currently the only definitive treatment for heart failure. However, transplantation is limited by donor availability.…

1
2
3
…
30
Next Page »